2020

The SARS-CoV-2 uses the human angiotensin-converting enzyme 2 (ACE2) receptor to enter a variety of cell types, notably in the upper and lower respiratory tract, although many cell types express ACE2. The affinity for viral binding may be linked to the level of ACE2 receptor expression in various tissues. In a recent Pre-print, authors analysed the association between polymorphisms in the ACE2 locus and COVID-19 severity.

Prof. Mohamed Ridha Barbouche from the Institut Pasteur de Tunis, gave insights on “Genetics of the immune response to Fungal Infections”. In his talk he highlighted the global fungal infection  burden (over 14.9 million cases per year with over 1.7 million deaths worldwide).These fungal infections are polyclinical, with well-known forms including: Invasive, Mucosal, Allergic, Chronic lung or deep tissue infection.

Authors in a pre-peer reviewed publication analyzed the Spike gene sequences of SARS-CoV-2 submitted to the Global Initiative on Sharing All Influenza Data (GISAID) database (https://nextstrain.org/ncov). They used a lentiviral pseudotype neutralizing antibody assay to evaluate the neutralizing sensitivity of the S-D614 and S-G614 mutation to convalescent sera from COVID-19 patients.

As the world continues to make significant progress around SARS-CoV-2 vaccination research and effective therapies for severe COVID-19, significantly less attention has been given to the acute neuropsychiatric sequelae of SARS-CoV-2 infection borne out of recent reports and its potential to become a significant global disease burden post-COVID-19. Acute and sub-acute neuropsychiatric manifestations that have...

In a recent IUIS Webinar, Eric Vivier presented data on longitudinal analysis of immune responses in the blood and bronchoalveolar lavage fluid (BALF) of patients at various stages of COVID-19 severity: paucisymptomatic, pneumonia and acute respiratory distress syndrome (ARDS). Anti-C5aR1 therapeutic monoclonal antibodies, Avdoralimab, prevented C5a-mediated human myeloid cell recruitment and activation...

Dexamethasone is a corticosteroid that was put into clinical trial to identify whether it could modulate immune-mediated lung injury and reduce progression to respiratory failure and death in COVID-19 patients. In a pre-peer reviewed paper, preliminary results of the RECOVERY trial was reported. This was a randomized trial comparing a range of possible treatments with usual care...

A recent publication in Nature Medicine investigated the acute antibody response to SARS-CoV-2 infection. Virus-specific IgG and IgM were measured in serum samples from asymptomatic and symptomatic individuals. In the asymptomatic group, 81.1% tested positive for IgG, and 83.8% of the symptomatic group tested positive for IgG approximately 3–4 weeks after exposure.

Authors in a pre-peer reviewed article established a quantitative RT-PCR assay for SARS-CoV-2 in breastmilk with a limit of detection of 250 copies per mL. They applied this to a series of 64 serial breastmilk samples from 18 SARS-CoV-2-infected women and found viral RNA in only one sample. After viral culture, they found the sample to be replication-incompetent and concluded that breast milk is not a source of SARS-CoV-2 infection to infants.

A recent study in the New England Journal of Medicine made a genome wide association analysis of 1980 patients with varying severities of COVID-19 to identify genetic factors associated with disease. The authors detected cross-replicating associations with rs11385942 at locus 3p21.31 and with rs657152 at locus 9q34.2. Locus 3p21.3 spans the genes SLC6A20, LZTFL1...

Researchers have developed a “pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates”. The induced antibodies neutralized 10 representative SARS-CoV-2 strains which suggests that there may be a possible broader neutralizing ability. “Three immunizations using two different doses...